72 related articles for article (PubMed ID: 32606188)
1. Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.
Numata T; Endo T; Yanai H; Ota K; Yamamoto Y; Shimizu K; Yamada H; Hayashihara K; Okauchi S; Satoh H; Yamada Y; Tamura T; Saito K; Kikuchi N; Kurishima K; Ishikawa H; Watanabe H; Shiozawa T; Hizawa N; Funayama Y; Hayashi S; Nakamura H; Yamashita T
In Vivo; 2020; 34(4):2095-2100. PubMed ID: 32606188
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
3. Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers.
Akita T; Ariyasu R; Kakuto S; Miyadera K; Kiritani A; Tsugitomi R; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Tasaka S; Nishio M
Thorac Cancer; 2024 Apr; 15(10):788-796. PubMed ID: 38400801
[TBL] [Abstract][Full Text] [Related]
4. Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer.
Li Y; Xuan J; Song Y; Qi W; He B; Wang P; Qin L
ACS Nano; 2016 Jan; 10(1):1640-7. PubMed ID: 26690745
[TBL] [Abstract][Full Text] [Related]
5. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract][Full Text] [Related]
6. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers.
Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
[TBL] [Abstract][Full Text] [Related]
7. Role of CYFRA 21-1 and CEA as prognostic and predictive markers in locally advanced and metastatic gastric carcinoma.
Gopal V; Nisha Y; Ganesan P; Kayal S; Bobby Z; Adithan S; Penumadu P; Ramakrishnalay VP; Bandlamudi BP; Bahttacharjee A; Dahagama S; Dubashi B
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261458
[TBL] [Abstract][Full Text] [Related]
8. Variability of serum CYFRA 21 - 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis.
Minamibata A; Kono Y; Arimoto T; Marunaka Y; Takayama K
BMC Pulm Med; 2023 Sep; 23(1):344. PubMed ID: 37705035
[TBL] [Abstract][Full Text] [Related]
9. Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.
Bronte G; Cafaro A; Pasini L; Priano I; Andrikou K; Cravero P; Burgio MA; Delmonte A; Crinò L
Expert Rev Anticancer Ther; 2021 Aug; 21(8):809-817. PubMed ID: 33905667
[No Abstract] [Full Text] [Related]
10. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Chuang CH; Chen HL; Chang HM; Tsai YC; Wu KL; Chen IH; Chen KC; Lee JY; Chang YC; Chen CL; Tu YK; Hung JY; Yang CJ; Chong IW
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921762
[TBL] [Abstract][Full Text] [Related]
12. Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
Ng TL; Johnson A; Nemenoff RA; Hsieh E; Osypuk AA; van Bokhoven A; Li H; Camidge DR; Schenk EL
J Thorac Oncol; 2021 Mar; 16(3):486-491. PubMed ID: 33307191
[TBL] [Abstract][Full Text] [Related]
13. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
14. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A
Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
17. Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions.
Dilek ON; Arslan Kahraman Dİ; Kahraman G
World J Gastrointest Surg; 2024 Apr; 16(4):999-1007. PubMed ID: 38690060
[TBL] [Abstract][Full Text] [Related]
18. CtDNA based molecular residual disease outcompetes carcinoembryonic antigen in predicting postoperative recurrence of non-small cell lung cancer.
Li HJ; Zhang JT; Dong S; Yang XN; Cui SR; Wu YL; Zhong WZ
J Thorac Dis; 2024 Jan; 16(1):423-429. PubMed ID: 38410594
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers for the early detection of bone metastases.
Hao Y; Zhang F; Ma Y; Luo Y; Zhang Y; Yang N; Liu M; Liu H; Li J
Front Oncol; 2023; 13():1188357. PubMed ID: 37404755
[TBL] [Abstract][Full Text] [Related]
20. Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning.
Zhou Z; Guo W; Liu D; Micha JRN; Song Y; Han S
Sci Rep; 2023 Mar; 13(1):4469. PubMed ID: 36934139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
